

# A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

NCT07279428

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Sichuan Baili Pharmaceutical Co., Ltd.
Enrollment	33 participants

## Key Eligibility Criteria

---

### Inclusion (14)

- Voluntarily sign the informed consent form and comply with the protocol requirements;
- No gender restrictions;
- Age: e18 years and d75 years (Phase Ia); e18 years (Phase Ib);
- Expected survival time e3 months;
- Locally advanced or metastatic digestive tract tumors and other solid tumors;
- ... and 9 more (see full listing online)

### Exclusion (21)

- Use of chemotherapy, biological therapy, or immunotherapy within 4 weeks prior to the first dose or within 5 half-lives;
- History of severe heart disease;
- QT interval prolongation, complete left bundle branch block, or third-degree atrioventricular block;
- Active autoimmune or inflammatory diseases;
- Diagnosis of other malignancies within 5 years prior to the first dose;
- ... and 16 more (see full listing online)

## Locations (1 total)

---

Beijing Cancer Hospital, Beijing, Beijing Municipality, China